Table 1 Demographic and clinical characteristics.
All N = 356 | BI N = 166 | NBI N = 190 | P-value | |
|---|---|---|---|---|
Male sex | 44 (12.4%) | 21 (12.7%) | 23 (12.1%) | 1 |
Age (years), mean (SD) | 43 (13.8) | 42 (13.1) | 43.9 (14.3) | 0.196 |
Charlson index | 0.315 | |||
Mean (SD) | 1.5 (1) | 1.6 (1.1) | 1.4 (0.9) | |
Median (IQR) | 1 (1—1) | 1 (1—2) | 1 (1—1) | |
Missing | 1 (0.3%) | 0 (0%) | 1 (0.5%) | |
Hospitalizations in last 12 months | 0.002 | |||
None | 212 (60.1%) | 114 (69.5%) | 98 (51.9%) | |
1 | 118 (33.4%) | 41 (25%) | 77 (40.7%) | |
2–4 | 23 (6.5%) | 9 (5.5%) | 14 (7.4%) | |
Missing | 3 (0.8%) | 1 (0.6%) | 2 (1%) | |
Comorbidities N (%) | 0.267 | |||
None | 176 (49.4%) | 82 (49.4%) | 94 (49.5%) | |
1 | 90 (25.3%) | 45 (27.1%) | 45 (23.7%) | |
2–4 | 80 (22.5%) | 32 (19.3%) | 48 (25.3%) | |
5 or more | 10 (2.8%) | 7 (4.2%) | 3 (1.6%) | |
CVD | 40 (11.2%) | 18 (10.8%) | 22 (11.6%) | 0.959 |
Diabetes | 10 (2.8%) | 3 (1.8%) | 7 (3.7%) | 0.348 |
Pulmonary | 14 (3.9%) | 8 (4.8%) | 6 (3.2%) | 0.595 |
Renal | 21 (5.9%) | 16 (9.6%) | 5 (2.6%) | 0.01 |
Hepatic | 20 (5.6%) | 13 (7.8%) | 7 (3.7%) | 0.143 |
Cancer | 14 (3.9%) | 7 (4.2%) | 7 (3.7%) | 1 |
Disease duration (in years) | 0.001 | |||
Mean (SD) | 11 (9) | 12.2 (8.9) | 9.9 (8.9) | |
Median (IQR) | 9.2 (3.4—16.6) | 10.2 (4.7—18.1) | 7.6 (2—15.7) | |
Missing | 2 (0.6%) | 0 (0%) | 2 (1%) | |
SLEDAI-2K | 0.195 | |||
Mean (SD) | 10.2 (7.5) | 10.4 (7) | 10 (8) | |
Median (IQR) | 8 (5—14) | 8.5 (6—12) | 8 (4—14) | |
Missing | 2 (0.6%) | 0 (0%) | 2 (1%) | |
SLICC-DI | 0.649 | |||
Mean (SD) | 1.2 (1.5) | 1.2 (1.6) | 1.2 (1.5) | |
Median (IQR) | 1 (0—2) | 1 (0—2) | 1 (0—2) | |
Missing | 4 (1.1%) | 0 (0%) | 4 (2.1%) | |
BILAG involvement (phenotypes), N (%) | ||||
Musculoskeletal | 186 (52.2%) | 97 (58.4%) | 89 (46.8%) | 0.038 |
Mucocutaneous | 151 (42.4%) | 73 (44%) | 78 (41.1%) | 0.653 |
Renal | 130 (36.5%) | 56 (33.7%) | 74 (38.9%) | 0.364 |
Haematological | 115 (32.2%) | 60 (36.1%) | 55 (28.9%) | 0.182 |
Cardiorespiratory | 63 (17.7%) | 32 (19.3%) | 31 (16.3%) | 0.554 |
Neuropsychiatric | 57 (16%) | 27 (16.3%) | 30 (15.8%) | 1 |
Vasculitis | 29 (8.1%) | 16 (9.6%) | 13 (6.8%) | 0.442 |
Ophthalmic | 12 (3.4%) | 7 (4.2%) | 5 (2.6%) | 0.594 |
Gastrointestinal | 8 (2.2%) | 3 (1.8%) | 5 (2.6%) | 0.729 |
missing | 0 (0%) | 0 (0%) | 0 (0%) | |
Concomitant therapies | ||||
Glucocorticoids | 303 (85.4%) | 146 (88%) | 157 (83.1%) | 0.251 |
Hydroxychloroquine | 247 (69.6%) | 118 (71.1%) | 129 (68.3%) | 0.644 |
Concomitant non-biologic therapy | ||||
Mycophenolate | 52 (14.6%) | 3 (1.8%) | 49 (25.8%) | < 0.001 |
Azathioprine | 39 (11%) | 1 (0.6%) | 38 (20%) | < 0.001 |
Cyclophosphamide | 12 (3.4%) | 0 (0%) | 12 (6.3%) | 0.003 |
Methotrexate | 44 (12.4%) | 2 (1.2%) | 42 (22.1%) | < 0.001 |
Cyclosporine | 18 (5.1%) | 3 (1.8%) | 15 (7.9%) | 0.018 |
Leflunomide | 2 (0.6%) | 0 (0%) | 2 (1.1%) | 0.501 |
Tacrolimus | 2 (0.6%) | 0 (0%) | 2 (1.1%) | 0.501 |
Other non-biologic | 1 (0.3%) | 0 (0%) | 1 (0.5%) | 1 |
Concomitant biologic therapy | ||||
Rituximab | 24 (6.7%) | 24 (14.5%) | 0 (0%) | < 0.001 |
Belimumab | 142 (39.9%) | 142 (85.5%) | 0 (0%) | < 0.001 |
Other biologic | 0 (0%) | 0 (0%) | 0 (0%) | NA |
